Prof Andrew Spencer MBBS FRACP FRCPA DM

Head of the Malignant Haematology & Stem Cell Transplantation Service

He completed his medical training in clinical and laboratory haematology in 1992. Subsequently, he was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into B-cell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London.

Andrew moved to The Alfred in 1999 where he established an independent translational research program. In parallel he established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology & Stem Cell Transplantation Service in 2007.

Most significant trial

The ALLG MM17 trial for myeloma patients who fail to respond to standard treatment. This group of patients has historically had poor survival rates. Professor Spencer’s approach exploring the use of Kyprolis and thalidomide has demonstrated very high response rates, including patients becoming minimal residual disease (MRD) negative. 

Find out more about Andrew's research interests.

Department

• Clinical Haematology
• Ronald Sawers Haemophilia Centre (HTC)